Back to Search Start Over

Gastrointestinal dysfunction and enteric neurotoxicity following treatment with anticancer chemotherapeutic agent 5-fluorouracil

Authors :
Kulmira Nurgali
Joel C. Bornstein
Rachel M McQuade
Raquel Abalo
Vanesa Stojanovska
Elizabeth L. Donald
University of Victoria
Source :
Digital.CSIC. Repositorio Institucional del CSIC, instname
Publication Year :
2016

Abstract

[Background]: The use of the anticancer chemotherapeutic agent 5-fluorouracil (5-FU) is often limited by nausea, vomiting, constipation, and diarrhea; these side-effects persist long after treatment. The effects of 5-FU on enteric neurons have not been studied and may provide insight into the mechanisms underlying 5-FU-induced gastrointestinal dysfunction. [Methods]: Balb/c mice received intraperitoneal injections of 5-FU (23 mg/kg) 3 times/week for 14 days. Gastrointestinal transit was analysed in vivo prior to and following 3, 7, and 14 days of 5-FU treatment via serial x-ray imaging. Following 14 days of 5-FU administration, colons were collected for assessment of ex vivo colonic motility, gross morphological structure, and immunohistochemical analysis of myenteric neurons. Fecal lipocalin-2 and CD45 leukocytes in the colon were analysed as markers of intestinal inflammation. [Key Results]: Short-term administration of 5-FU (3 days) increased gastrointestinal transit, induced acute intestinal inflammation and reduced the proportion of neuronal nitric oxide synthase-immunoreactive neurons. Long-term treatment (7, 14 days) resulted in delayed gastrointestinal transit, inhibition of colonic migrating motor complexes, increased short and fragmented contractions, myenteric neuronal loss and a reduction in the number of ChAT-immunoreactive neurons after the inflammation was resolved. Gross morphological damage to the colon was observed following both short- and long-term 5-FU treatment. [Conclusions & Inferences]: Our results indicate that 5-FU induces accelerated gastrointestinal transit associated with acute intestinal inflammation at day 3 after the start of treatment, which may have led to persistent changes in the ENS observed after days 7 and 14 of treatment contributing to delayed gastrointestinal transit and colonic dysmotility.<br />This work was supported by a research grant from Victoria University.

Details

ISSN :
13652982
Volume :
28
Issue :
12
Database :
OpenAIRE
Journal :
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
Accession number :
edsair.doi.dedup.....657276df7a76d99e4654b498dd7c93ca